Sunflower Pharmaceuticals Group Co Ltd
Sunflower Pharmaceutical Group Co.,Ltd engages in the research and development, manufacturing, and marketing of Chinese patent medicines in China and internationally. The company produces chemical and biological medicines, and health care products. It also provides products covering various therapeutic areas, including pediatrics, gynecology, adult digestive system, respiratory and cold, rheumati… Read more
Sunflower Pharmaceuticals Group Co Ltd (002737) - Net Assets
Latest net assets as of September 2025: CN¥4.23 Billion CNY
Based on the latest financial reports, Sunflower Pharmaceuticals Group Co Ltd (002737) has net assets worth CN¥4.23 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.12 Billion) and total liabilities (CN¥891.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.23 Billion |
| % of Total Assets | 82.6% |
| Annual Growth Rate | 17.83% |
| 5-Year Change | 35.37% |
| 10-Year Change | 75.83% |
| Growth Volatility | 41.82 |
Sunflower Pharmaceuticals Group Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Sunflower Pharmaceuticals Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sunflower Pharmaceuticals Group Co Ltd (2011–2024)
The table below shows the annual net assets of Sunflower Pharmaceuticals Group Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.59 Billion | -8.29% |
| 2023-12-31 | CN¥5.00 Billion | +12.75% |
| 2022-12-31 | CN¥4.44 Billion | +12.80% |
| 2021-12-31 | CN¥3.94 Billion | +16.05% |
| 2020-12-31 | CN¥3.39 Billion | -1.13% |
| 2019-12-31 | CN¥3.43 Billion | -0.21% |
| 2018-12-31 | CN¥3.44 Billion | +8.71% |
| 2017-12-31 | CN¥3.16 Billion | +12.74% |
| 2016-12-31 | CN¥2.80 Billion | +7.43% |
| 2015-12-31 | CN¥2.61 Billion | +14.51% |
| 2014-12-31 | CN¥2.28 Billion | +162.33% |
| 2013-12-31 | CN¥869.02 Million | +14.59% |
| 2012-12-31 | CN¥758.39 Million | +39.55% |
| 2011-12-31 | CN¥543.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sunflower Pharmaceuticals Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1052.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.57 Billion | 58.63% |
| Common Stock | CN¥584.00 Million | 13.34% |
| Other Comprehensive Income | CN¥545.20 Million | 12.45% |
| Other Components | CN¥682.26 Million | 15.58% |
| Total Equity | CN¥4.38 Billion | 100.00% |
Sunflower Pharmaceuticals Group Co Ltd Competitors by Market Cap
The table below lists competitors of Sunflower Pharmaceuticals Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gr. Sarantis S.A
PINK:SRTSF
|
$432.15 Million |
|
Surya Esa Perkasa Tbk
JK:ESSA
|
$432.22 Million |
|
Chinhung International Inc. Pfd. Series 2
KO:002787
|
$432.23 Million |
|
SCOR PK
PINK:SCRYY
|
$432.24 Million |
|
NORTHRIM BA. DL-01
F:NRI
|
$432.03 Million |
|
Sichuan Golden Summit Group Joint Stock Co Ltd
SHG:600678
|
$431.97 Million |
|
Neurones
PA:NRO
|
$431.86 Million |
|
China Education Group Holdings Limited
PINK:CEGHF
|
$431.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sunflower Pharmaceuticals Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,763,440,300 to 4,379,138,713, a change of -384,301,587 (-8.1%).
- Net income of 492,045,429 contributed positively to equity growth.
- Dividend payments of 885,199,386 reduced retained earnings.
- Other comprehensive income increased equity by 532,915,165.
- Other factors decreased equity by 524,062,795.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥492.05 Million | +11.24% |
| Dividends Paid | CN¥885.20 Million | -20.21% |
| Other Comprehensive Income | CN¥532.92 Million | +12.17% |
| Other Changes | CN¥-524.06 Million | -11.97% |
| Total Change | CN¥- | -8.07% |
Book Value vs Market Value Analysis
This analysis compares Sunflower Pharmaceuticals Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.69x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 10.48x to 1.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥1.21 | CN¥12.64 | x |
| 2012-12-31 | CN¥1.67 | CN¥12.64 | x |
| 2013-12-31 | CN¥1.89 | CN¥12.64 | x |
| 2014-12-31 | CN¥5.08 | CN¥12.64 | x |
| 2015-12-31 | CN¥4.19 | CN¥12.64 | x |
| 2016-12-31 | CN¥4.53 | CN¥12.64 | x |
| 2017-12-31 | CN¥5.15 | CN¥12.64 | x |
| 2018-12-31 | CN¥5.58 | CN¥12.64 | x |
| 2019-12-31 | CN¥5.53 | CN¥12.64 | x |
| 2020-12-31 | CN¥5.51 | CN¥12.64 | x |
| 2021-12-31 | CN¥6.38 | CN¥12.64 | x |
| 2022-12-31 | CN¥7.20 | CN¥12.64 | x |
| 2023-12-31 | CN¥8.17 | CN¥12.64 | x |
| 2024-12-31 | CN¥7.48 | CN¥12.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sunflower Pharmaceuticals Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.24%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.57%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 1.33x
- Recent ROE (11.24%) is below the historical average (19.93%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 36.06% | 12.24% | 1.00x | 2.94x | CN¥137.94 Million |
| 2012 | 31.96% | 13.23% | 0.93x | 2.58x | CN¥160.94 Million |
| 2013 | 31.74% | 12.06% | 1.04x | 2.53x | CN¥180.10 Million |
| 2014 | 13.59% | 11.08% | 0.73x | 1.68x | CN¥79.50 Million |
| 2015 | 12.52% | 10.10% | 0.81x | 1.54x | CN¥61.69 Million |
| 2016 | 11.49% | 9.01% | 0.80x | 1.60x | CN¥39.28 Million |
| 2017 | 14.17% | 11.00% | 0.86x | 1.49x | CN¥124.71 Million |
| 2018 | 17.21% | 12.60% | 0.88x | 1.55x | CN¥235.99 Million |
| 2019 | 17.54% | 12.93% | 0.82x | 1.65x | CN¥243.01 Million |
| 2020 | 18.38% | 16.88% | 0.68x | 1.61x | CN¥266.43 Million |
| 2021 | 19.00% | 15.80% | 0.79x | 1.52x | CN¥333.80 Million |
| 2022 | 20.62% | 17.02% | 0.72x | 1.67x | CN¥446.75 Million |
| 2023 | 23.49% | 19.63% | 0.83x | 1.44x | CN¥642.80 Million |
| 2024 | 11.24% | 14.57% | 0.58x | 1.33x | CN¥54.13 Million |
Industry Comparison
This section compares Sunflower Pharmaceuticals Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sunflower Pharmaceuticals Group Co Ltd (002737) | CN¥4.23 Billion | 36.06% | 0.21x | $432.08 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |